文献速递产科母胎医学

扩展性无创产前筛查检测微缺失微重复综合征的潜力

The potential of expanded noninvasive prenatal screening for detection of microdeletion and microduplication syndromes.
PubMed 文献 · Prenat Diagn · 2021-07-03

多中心前瞻性研究纳入37,002例早孕期超声无异常的孕妇行NIPS-Plus检测,筛查阳性者经羊膜腔穿刺验证。36,970例超声阴性者中291例筛查阳性,其中54例提示MMS,MMS阳性预测值为50%;NIPS-Plus阴性孕妇所生儿童1岁时未见明显染色体病综合征征象。

要点

  • 超声无异常孕妇中NIPS-Plus可同时筛查常见非整倍体与MMS
  • 该人群MMS阳性预测值为50%,阳性需羊膜腔穿刺确诊
  • 建议超声联合NIPS-Plus并配合咨询作为一线产前筛查方案

核心结论

  • NIPS-Plus不仅可用于常规非整倍体筛查,也有潜力检出早孕期超声无显征象的微缺失微重复综合征。
  • 建议将超声联合NIPS-Plus并配合适当咨询作为所有孕妇的综合一线产前筛查方案。

研究设计与样本

  • 多中心前瞻性研究,纳入37,002例早孕期超声扫描无异常的孕妇接受NIPS-Plus检测。
  • 超声筛查阳性的孕妇未纳入本研究;筛查阳性者行羊膜腔穿刺确诊。

主要发现

  • 36,970例超声阴性孕妇中291例NIPS-Plus筛查阳性,提示237例非整倍体与54例MMS。
  • 羊膜腔穿刺后171例(72%)确诊为真阳性,含3例T13、10例T18、61例T21、70例SCAs和27例MMS。
  • 超声无异常者的MMS阳性预测值为50%。
  • NIPS-Plus阴性妊娠所生儿童1岁时常规临床检查未见明显染色体病综合征征象。

关键数值与推荐

  • NIPS-Plus筛查阳性291例中确诊真阳性171例(72%)。
  • 真阳性含3例T13、10例T18、61例T21、70例SCAs、27例MMS。
  • 超声无异常人群中MMS的阳性预测值为50%。

临床怎么用

  • 对早孕期超声无异常的所有孕妇,可考虑超声联合NIPS-Plus并配合适当咨询作为综合一线产前筛查方案。
  • NIPS-Plus筛查阳性者应行羊膜腔穿刺等产前诊断确诊,不宜直接据筛查结果作出诊断。

局限性

  • 超声筛查阳性孕妇被排除,结果不适用于该人群。
  • 摘要未报告MMS各具体类型分布及阴性预测值等数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To evaluate the clinical potential of a higher resolution noninvasive prenatal screening (NIPS-Plus) test for detection of microdeletion/microduplication syndromes (MMS) in addition to common aneuploidies. METHODS: In a multicenter prospective study, 37,002 pregnant women with unremarkable first-trimester ultrasound scans had a NIPS-Plus test. Ultrasound screen positive women were not included in this study. RESULTS: Of 36,970 ultrasound negative women there were 291 NIPS-Plus screen positive results indicating 237 aneuploidies and 54 MMS. Following amniocentesis, 171 (72%) were confirmed as genuine, comprising 3 T13s, 10 T18s, 61 T21s, 70 SCAs and 27 MMS. The PPV for MMS with unremarkable ultrasound findings was 50%. Routine clinical examination of children born from NIPS-Plus negative pregnancies revealed no obvious signs of chromosome disease syndromes at one year of age. CONCLUSIONS: NIPS-Plus has the potential for clinical utility not only for routine aneuploid screening but also for MMS that do not show overt signs during early pregnancy ultrasound screening. We suggest that ultrasound with NIPS-Plus in combination with appropriate counselling could be considered as a comprehensive first-tier prenatal screening approach for all pregnant women.

来源:Prenat Diagn,查看原文。版权归原作者所有。

引用

  1. Shi P, Wang Y, Liang H, et al. The potential of expanded noninvasive prenatal screening for detection of microdeletion and microduplication syndromes. Prenat Diagn. 2021. PMID: 34181751. doi:10.1002/pd.6002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。